反応式
[C:1]([NH:5][S:6]([C:9]1[CH:14]=[CH:13][CH:12]=[C:11]([C:15]2[N:23]3[C:18]([CH:19]=[N:20][C:21](S(C)=O)=[N:22]3)=[CH:17][CH:16]=2)[CH:10]=1)(=[O:8])=[O:7])([CH3:4])([CH3:3])[CH3:2].[F:27][C:28]([F:40])([F:39])[C:29]1[NH:30][C:31]2[CH:37]=[C:36]([NH2:38])[CH:35]=[CH:34][C:32]=2[N:33]=1>>[C:1]([NH:5][S:6]([C:9]1[CH:14]=[CH:13][CH:12]=[C:11]([C:15]2[N:23]3[C:18]([CH:19]=[N:20][C:21]([NH:38][C:36]4[CH:35]=[CH:34][C:32]5[N:33]=[C:29]([C:28]([F:40])([F:39])[F:27])[NH:30][C:31]=5[CH:37]=4)=[N:22]3)=[CH:17][CH:16]=2)[CH:10]=1)(=[O:8])=[O:7])([CH3:4])([CH3:3])[CH3:2]参加物
3
実験手順
Following the synthetic and purification procedures described in Example 1293d, N-tert-butyl-3-(2-methanesulfinyl-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-benzenesulfonamide (103 mg, 0.262 mmol) was coupled with 2-trifluoromethyl-3H-benzimidazol-5-ylamine (91 mg, 0.45 mmol) at 105° C. for 132 h to afford the title compound. Yield of TFA salt: 15 mg (26%) of brown powder; LC/MS: 529 (M+H); HPLC: 97% pure, RT=2.16 min; 1H NMR: (DMSO, δ) 9.68 (s, 1H), 9.07 (s, 1H), 8.53 (m, 2H), 8.02 (s, 1H), 7.86 (d, J=8.0, 1H), 7.83 (dd, J=9.1, 1.8, 1H), 7.75 (m, 3H), 7.25 (d, J=4.7, 1H), 7.03 (d, J=4.7, 1H), 1.12 (s, 9H)-benzimidazole NH presumably underwent rapid exchange with residual water.
後処理
- custompurification procedures
出典と根拠
- ORDレコード
- ord-dc4b933c2977468eb66ec76120b4f952
- 出典データセット
- uspto-grants-2013_06
- 特許番号
- US08471005B2
関連ノート
読み込み中…